News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Depomed, Inc. Announces Completion Of Phase I Clinical Trial With Gastroesophageal Reflux Disease Compound; Phase IIA Clinical Trial Planned
August 15, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Depomed, Inc. (Nasdaq:DEPO) today announced that it has completed a Phase I clinical trial to evaluate the delivery and absorption of a compound currently used to treat gastroesophageal reflux disease (GERD).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Phase 2
MORE ON THIS TOPIC
Obesity
Novo may have muscle advantage over Lilly in weight-loss race: preprint
April 17, 2026
·
2 min read
·
Tristan Manalac
Insights
Funding the future of European biotech
April 16, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Gene therapy
MeiraGTx, spying hope in a failed trial, buys back eye disease gene therapy from J&J
April 16, 2026
·
2 min read
·
Annalee Armstrong
diabetes
Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns
April 16, 2026
·
2 min read
·
Gabrielle Masson
